Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.

ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.

Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.

The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.